Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of
KRAS lung adenocarcinoma
PD-1 inhibition
PD-L1
inhibitor of differentiation
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Oct 2020
28 Oct 2020
Historique:
received:
22
09
2020
revised:
19
10
2020
accepted:
25
10
2020
entrez:
31
10
2020
pubmed:
1
11
2020
medline:
1
11
2020
Statut:
epublish
Résumé
The use of PD-1/PD-L1 checkpoint inhibitors in advanced NSCLC is associated with longer survival. However, many patients do not benefit from PD-1/PD-L1 blockade, largely because of immunosuppression. New immunotherapy-based combinations are under investigation in an attempt to improve outcomes.
Identifiants
pubmed: 33126649
pii: cancers12113169
doi: 10.3390/cancers12113169
pmc: PMC7693788
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fundación Merck Salud
ID : 17-PU-006
Organisme : Regional Government of Navarra
ID : 44/2017
Références
Nat Rev Cancer. 2005 Aug;5(8):603-14
pubmed: 16034366
Nat Commun. 2015 Apr 29;6:6840
pubmed: 25924227
Int J Mol Sci. 2019 May 09;20(9):
pubmed: 31075880
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
Cancer Discov. 2020 Jan;10(1):142-157
pubmed: 31582374
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Curr Opin Immunol. 2013 Apr;25(2):291-6
pubmed: 23561594
Cancer Immunol Immunother. 2020 Apr;69(4):513-522
pubmed: 31953577
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Science. 1992 Jul 24;257(5069):548-51
pubmed: 1636093
Immunity. 2009 May;30(5):626-35
pubmed: 19464985
Oncogene. 2001 Dec 20;20(58):8334-41
pubmed: 11840326
Oncoimmunology. 2018 May 31;7(8):e1466016
pubmed: 30221065
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
J Exp Med. 1999 Sep 6;190(5):617-27
pubmed: 10477547
Clin Cancer Res. 2011 Jun 15;17(12):4155-66
pubmed: 21540238
Immunol Cell Biol. 2011 Jul;89(5):610-8
pubmed: 21102536
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Immunity. 2005 Mar;22(3):371-83
pubmed: 15780993
J Immunol. 2014 Jul 15;193(2):663-672
pubmed: 24920844
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Cancer Lett. 2017 Aug 28;402:43-51
pubmed: 28549790
J Immunol. 2007 Nov 1;179(9):5916-26
pubmed: 17947665
Genome Biol. 2004;5(10):R80
pubmed: 15461798
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Lancet Oncol. 2016 Nov;17(11):1464-1465
pubmed: 27819227
J Exp Med. 1998 Dec 21;188(12):2357-68
pubmed: 9858522
Clin Cancer Res. 2019 Aug 1;25(15):4592-4602
pubmed: 30824587
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Nat Rev Cancer. 2014 Feb;14(2):77-91
pubmed: 24442143
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
Oncogene. 2018 Jul;37(27):3672-3685
pubmed: 29622797
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
Mayo Clin Proc. 2008 May;83(5):584-94
pubmed: 18452692
Front Pharmacol. 2019 Mar 12;10:230
pubmed: 30930778
Cell Rep. 2019 Oct 1;29(1):62-75.e7
pubmed: 31577956
J Exp Med. 2010 Oct 25;207(11):2469-77
pubmed: 20921286
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Mol Cell Biol. 2004 Sep;24(17):7313-23
pubmed: 15314144
Cancer Cell. 2002 Dec;2(6):473-83
pubmed: 12498716
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Oncotarget. 2017 Nov 25;8(66):110693-110707
pubmed: 29299180
Cancer Res. 2019 Feb 1;79(3):625-638
pubmed: 30563891
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Int J Cancer. 2014 Dec 1;135(11):2516-27
pubmed: 24473991
Eur J Immunol. 2004 Mar;34(3):613-622
pubmed: 14991590
Crit Rev Immunol. 2015;35(1):33-48
pubmed: 25746046
J Transl Med. 2015 Aug 07;13:257
pubmed: 26248464